Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation, pharmacokinetics and safety study of CetuGEX in EGFR-positive advanced or metastatic solid tumors
2010-019552-50Phase 2Completed
- Sponsor
- Glycotope
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomuzotuximab in Non-hematologic malignancy, sponsored by Glycotope. Primary endpoint: Safety and tolerability of CetuGEX. Started Mar 2010; status: completed.
02
Drugs
tomuzotuximab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2010-019552-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019552-50.